期刊
NEPHROLOGY DIALYSIS TRANSPLANTATION
卷 37, 期 6, 页码 1014-1023出版社
OXFORD UNIV PRESS
DOI: 10.1093/ndt/gfaa294
关键词
albuminuria; CKD; clinical trial; diabetic kidney disease; mineralocorticoid receptor antagonist
资金
- Bayer AG
Research has found that finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, can protect the kidneys and hearts of patients with chronic kidney disease and type 2 diabetes. The FIDELIO-DKD and FIGARO-DKD trials are investigating the efficacy and safety of finerenone on kidney failure and cardiovascular outcomes in T2D patients with different stages of kidney disease.
Despite the standard of care, patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) progress to dialysis, are hospitalized for heart failure and die prematurely. Overactivation of the mineralocorticoid receptor (MR) causes inflammation and fibrosis that damages the kidney and heart. Finerenone, a nonsteroidal, selective MR antagonist, confers kidney and heart protection in both animal models and Phase II clinical studies; the effects on serum potassium and kidney function are minimal. Comprising the largest CKD outcomes program to date, FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) and FIGARO-DKD (FInerenone in reducinG cArdiovascular moRtality and mOrbidity in Diabetic Kidney Disease) are Phase III trials investigating the efficacy and safety of finerenone on kidney failure and cardiovascular outcomes from early to advanced CKD in T2D. By including echocardiograms and biomarkers, they extend our understanding of pathophysiology; by including quality of life measurements, they provide patient-centered outcomes; and by including understudied yet high-risk cardiorenal subpopulations, they have the potential to widen the scope of therapy in T2D with CKD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据